338776-97-9

Basic information

• Product Name: 3-(CHLOROMETHYL)-5-(3,4-DICHLOROPHENYL)ISOXAZOLE
• Synonyms: 3-(CHLOROMETHYL)-5-(3,4-DICHLOROPHENYL)ISOXAZOLE;3-(chloromethyl)-5-(3,4-dichlorophenyl)-1,2-oxazole
• CAS NO: 338776-97-9
• Molecular Formula: C₁₀H₆Cl₃NO
• Molecular Weight: 262.52
• Mol File: 338776-97-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(CHLOROMETHYL)-5-(3,4-DICHLOROPHENYL)ISOXAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(CHLOROMETHYL)-5-(3,4-DICHLOROPHENYL)ISOXAZOLE(338776-97-9)
• EPA Substance Registry System: 3-(CHLOROMETHYL)-5-(3,4-DICHLOROPHENYL)ISOXAZOLE(338776-97-9)

Safety Data

• Hazardous Substances Data: 338776-97-9(Hazardous Substances Data)

Upstream product

• 1011732-51-6 (5R,7S)-1-(3-fluorophenyl)-7-methyl-1,3,8-triazaspiro[4.5]decane-2,4-dione 
• 100-44-7 benzyl chloride 
• 76-05-1 trifluoroacetic acid 
• 2642-63-9 3',4'-dichloroacetophenone 
• 1475-11-2 1-(3,4-dichlorophenyl)ethan-1-ol 
• 6287-38-3 3,4-dichlorobenzaldehyde 

Relevant articles and documents

Design, synthesis and structure-based optimization of novel isoxazole-containing benzamide derivatives as FtsZ modulators

Antibiotic resistance among clinically significant bacterial pathogens is becoming a prevalent threat to public health, and new antibacterial agents with novel mechanisms of action hence are in an urgent need. Utilizing computational docking method and structure-based optimization strategy, we rationally designed and synthesized two series of isoxazol-3-yl- and isoxazol-5-yl-containing benzamide derivatives that targeted the bacterial cell division protein FtsZ. Evaluation of their activity against a panel of Gram-positive and -negative pathogens revealed that compounds B14 and B16 that possessed the isoxazol-5-yl group showed strong antibacterial activity against various testing strains, including methicillin-resistant Staphylococcus aureus and penicillin-resistant S. aureus. Further molecular biological studies and docking analyses proved that the compound functioned as an effective inhibitor to alter the dynamics of FtsZ self-polymerization via a stimulatory mechanism, which finally terminated the cell division and caused cell death. Taken together, these results could suggest a promising chemotype for development of new FtsZ-targeting bactericidal agent.

Design, synthesis and biological evaluation of stilbene derivatives as novel inhibitors of protein tyrosine phosphatase 1B

By imitating the scaffold of lithocholic acid (LCA), a natural steroidal compound displaying Protein Tyrosine Phosphatase 1B (PTP1B) inhibitory activity, a series of stilbene derivatives containing phenyl-substituted isoxazoles were designed and synthesized. The structures of the title compounds were confirmed by 1H-NMR, 13C-NMR and HRMS. Activities of the title compounds were evaluated on PTP1B and the homologous enzyme TCPTP by using a colorimetric assay. Most of the target compounds had good activities against PTP1B. Among them, compound 29 (IC50 = 0.91 ± 0.33 μM), characterized by a 5-(2,3-dichlorophenyl) isoxazole moiety, exhibited an activity about 14-fold higher than the lead compound LCA and a 4.2-fold selectivity over TCPTP. Compound 29 was identified as a competitive inhibitor of PTP1B with a Ki value of 0.78 μM in enzyme kinetic studies.

SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

The present invention is directed to spiropiperidine compounds of formula (I) and tautomers thereof, which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as